Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Cyduct Diagnostics does not have enough data to calculate 3-Year RORE %.
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Cyduct Diagnostics 3-Year RORE % Related Terms
Cyduct Diagnostics 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Cyduct Diagnostics's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cyduct Diagnostics 3-Year RORE % Chart
Cyduct Diagnostics Annual Data
Trend
3-Year RORE %
Cyduct Diagnostics Quarterly Data
3-Year RORE %
CYDX vs SECI, QTXB, ASNB: 3-Year RORE % Comparison
For the Medical Devices subindustry, Cyduct Diagnostics's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cyduct Diagnostics 3-Year RORE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cyduct Diagnostics's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Cyduct Diagnostics's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in . 20 and 3-year before.
Cyduct Diagnostics (CYDX) has a 3-Year RORE % of 0.00 as of . 20. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Cyduct Diagnostics and its competitors.
Is Cyduct Diagnostics' 3-Year RORE % too high?
Cyduct Diagnostics' current 3-Year RORE % is 0.00.
How does Cyduct Diagnostics' 3-Year RORE % compare to SECI and QTXB?
Cyduct Diagnostics' 3-Year RORE % of 0.00 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Medical Devices & Instruments company?
A good 3-Year RORE % depends on the Medical Devices & Instruments industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Cyduct Diagnostics and its competitors. Cyduct Diagnostics's current 3-Year RORE % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cyduct Diagnostics stock overvalued right now?
Cyduct Diagnostics (CYDX) has a current 3-Year RORE % of 0.00. The current 3-Year RORE % is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Cyduct Diagnostics (CYDX), the current 3-Year RORE % is 0.00 as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cyduct Diagnostics Inc is a clinical-stage diagnostic company. It focuses on creating and enhancing a portfolio of technologies and assets based on the early assessment and detection of Breast Cancer. Its technology platform of MammoView devices is a single-use, high-margin product that assesses, screens, detects, monitors, and facilitates the treatment of identifiable changes that distinguish variations in breast health. The company markets these products under its Solos Endoscopy brand, along with a line of branded surgical instruments, manufactured by third parties to its design specifications, mainly endoscopes and hand-held surgical instruments for the minimally invasive surgery market.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CYDX has been successfully added to your 
